Sharpen Your Clinical & Commercial Strategy for Novel Patient-Friendly Wet AMD, DME, DR & RVO Drugs

March 18 - 20, 2025 | Boston, MA

Global biopharmaceutical leaders continue to make significant strides in retinal disease treatments; as Bayer and Regeneron make headway with its high-dose version of Eylea (Eylea HD), Roche’s Vabysmo is providing strong competition and has rapidly increased its market share across wet AMD and DME.

Additionally, biotechs are pioneering new breakthroughs such as Outlook Therapeutics developing bevacizumab for FDA approval in ophthalmic indications, while Ocular Therapeutix progresses innovative sustained-release drug delivery systems to extend treatment intervals and enhance patient outcomes.

The 2025 Wet AMD & Diabetic Eye Disease Drug Summit is the only industry-led event dedicated to exploring the latest advancements, strategic collaborations, and cutting-edge research driving the field of retinal disease treatment forward.

Join a dynamic community of 70+ global leaders, including translational, clinical, and commercial experts as they gather at this premier summit. Attendees will gain unparalleled insights into emerging therapies, adaptive trial designs, and the latest clinical studies aimed at improving treatment efficacy and patient care.

2025 Agenda Highlights:

5th Wet AMD & Diabetic Eye Disease Drug Development bullet point

Bayer: Showcasing the NEON-NPDR trial for runcaciguat, highlighting its potential to enhance retinal health by activating soluble guanylate cyclase and improving blood flow in NPDR

5th Wet AMD & Diabetic Eye Disease Drug Development bullet point

Sanofi: Presenting novel device innovations and refined dosing strategies aimed at streamlining retinal vascular treatment administration and enhancing patient adherence

5th Wet AMD & Diabetic Eye Disease Drug Development bullet point

Ocular Therapeutix: Introducing AXPAXLI (OTX-TKI), a sustained-release hydrogel implant promising extended treatment intervals for wet AMD and DR 

5th Wet AMD & Diabetic Eye Disease Drug Development bullet point

Outlook Therapeutics: Highlighting the advancements of ONS-5010, a next-gen bevacizumab designed for reliable, consistent care in retinal therapy 

5th Wet AMD & Diabetic Eye Disease Drug Development bullet point

HuidaGene Therapeutics: Unveiling the first CRISPR/RNA-targeting therapy, HG202, developed to address neovascular AMD with innovative gene-editing technology

5th Wet AMD & Diabetic Eye Disease Drug Development Brochure Cover

DOWNLOAD THE 2025 FULL EVENT GUIDE

World-Class Speaker Faculty Includes:

Previously Attending Companies Include:

Boehringer Ingelheim Logo
Bayer Logo
Novartis Logo
Ocuphire Pharma Logo
Sanofi Logo
Kyowa Kirin Pharma Logo
EyePoint Pharmaceuticals Logo
ViAn Therapeutics Logo
EOM Pharmaceuticals Logo
Macular Society Logo
Annexin Pharmaceuticals Logo
Inflammasome Therapeutics Logo
Nanoscope Therapeutics Logo
Beacon Therapeutics Logo
AMD Therapeutics Logo
Aviceda Therapeutics Logo

Hear From Past Attendees:

“Close communications and networking opportunities with qualified individuals, and the latest R&D information.” 

Hiroaki Serizawa, Chief Executive Officer, AMD Therapeutics

AMD Therapeutics Logo
Annexin Pharmaceuticals Logo

“The intimate very friendly setting allowed for a truly meaningful interactions between speakers and the audience” 

Anna Frostegard, Chief Scientific & Medical Officer, Annexin Pharmaceuticals

“There were some really useful discussions and I was impressed with the quality of the agenda and content” 

Peter Bloomfield, Director, Research, Macular Society

Macular Society Logo

Other Events in the Ophthalmology & Sensory Series: